BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A Case of Infantile Cardiac Rhabdomyoma Complicated by Tuberous Sclerosis.

We experienced a case with fetal cardiac tumor, which was diagnosed by prenatal ultrasonographic examination, and the diagnosis was confirmed after birth.

The computed tomography of the head revealed the intracranial multiple calcification lesions, which indicated the symptoms of tuberous sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Pediatr. 2003 Nov;143(5):620-4 [14615733.001]

[Cites] Pediatr Cardiol. 2004 May-Jun;25(3):252-73 [15360117.001]

[Cites] Ultrasound Obstet Gynecol. 2008 Mar;31(3):289-95 [18307215.001]

[Cites] Am J Cardiol. 1990 Nov 15;66(17):1247-9 [2239731.001]

(PMID = 28352373.001).

[ISSN] 1923-2829

[Journal-full-title] Cardiology research

[ISO-abbreviation] Cardiol Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Keywords] NOTNLM ; Fetal cardiac tumor / Prenatal diagnosis / Rhabdomyoma / Tuberous sclerosis

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Reducing the Discrepancy Between ASTER and MODIS Land Surface Temperature Products.

Human-induced global warming has significantly increased the importance ofsatellite monitoring of land surface temperature (LST) on a global scale.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28903278.001).

[ISSN] 1424-8220

[Journal-full-title] Sensors (Basel, Switzerland)

[ISO-abbreviation] Sensors (Basel)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

[Keywords] NOTNLM ; ASTER / MODIS / land surface temperature / remote sensing / retrieval algorithm / scale effects / surface emissivity / terrain effects

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A Wetness Index Using Terrain-Corrected Surface Temperature and Normalized Difference Vegetation Index Derived from Standard MODIS Products: An Evaluation of Its Use in a Humid Forest-Dominated Region of Eastern Canada.

In this paper we develop a method to estimate land-surface water content in amostly forest-dominated (humid) and topographically-varied region of eastern Canada.

Theapproach is centered on a temperature-vegetation wetness index (TVWI) that uses standard 8-day MODIS-based image composites of land surface temperature (T_S) and surface reflectanceas primary input.

In an attempt to improve estimates of TVWI in high elevation areas, terrain-induced variations in T_S are removed by applying grid, digital elevation model-basedcalculations of vertical atmospheric pressure to calculations of surface potential temperature(θS).

Here, θ_S corrects T_S to the temperature value to what it would be at mean sea level (i.e.,~101.3 kPa) in a neutral atmosphere.

The vegetation component of the TVWI uses 8-daycomposites of surface reflectance in the calculation of normalized difference vegetation index(NDVI) values.

A comparison of spatially-averaged field measurements of volumetric soil water content (VSWC) and TVWI for the 2003-2005 period revealed that variation with time to both was similar in magnitudes.

An evaluation of the long-term spatial distribution of land-surface wetness generated with the new θ_S-NDVI function and a process-based model of soil water content showed a strong relationship (i.e., r² = 95.7%).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28903212.001).

[ISSN] 1424-8220

[Journal-full-title] Sensors (Basel, Switzerland)

[ISO-abbreviation] Sensors (Basel)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

[Keywords] NOTNLM ; MODIS standard products / normalized difference vegetation index / potential temperature / soils / surface / temperature-vegetation wetness index / vegetation / water content.

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acral lesions in tuberous sclerosis complex: insights into pathogenesis.

BACKGROUND: Patients with tuberous sclerosis complex (TSC) are predisposed to developing ungual fibromas and other acral lesions.

OBJECTIVE: We sought to determine the numbers, types, and locations of acral skin lesions in TSC.

METHODS: We examined and photographed 76 adult women with TSC.

CONCLUSIONS: Examination of patients for skin lesions of TSC could be improved by including inspection for longitudinal nail grooves, red comets, longitudinal leukonychia, and splinter hemorrhages in addition to ungual fibromas.

The anatomic distribution of TSC ungual fibromas is not random and appears consistent with trauma-promoted tumor formation.

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Nail Diseases.

MedlinePlus Health Information. consumer health - Skin Conditions.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

[Cites] Arch Dermatol. 1962 Feb;85:209-26 [14479476.001]

[Cites] Int J Dermatol. 1998 Dec;37(12):911-7 [9888331.001]

[Cites] J Child Neurol. 1998 Dec;13(12):624-8 [9881533.001]

[Cites] Postgrad Med J. 1964 Oct;40:595-600 [14220406.001]

[Cites] Br J Dermatol. 1996 Jul;135(1):1-5 [8776349.001]

[Cites] Arch Dermatol. 1995 Dec;131(12):1465-6 [7492148.001]

[Cites] J Dermatol. 2004 Dec;31(12):993-7 [15801264.001]

[Cites] Ann Intern Med. 2005 Aug 16;143(4):313-4 [16103482.001]

[Cites] J Exp Med. 2005 Sep 5;202(5):617-24 [16129702.001]

[Cites] Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S49-66 [16457017.001]

[Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]

[Cites] Adv Dermatol. 2006;22:181-200 [17249302.001]

[Cites] Genet Med. 2007 Feb;9(2):88-100 [17304050.001]

[Cites] J Am Acad Dermatol. 2007 May;56(5):786-90 [17239986.001]

[Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]

[Cites] Cutis. 2007 Aug;80(2):137-40 [17944173.001]

[Cites] Dermatol Surg. 2008 Mar;34(3):364-9 [18177395.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3539-44 [18292222.001]

[Cites] Arch Dermatol. 2008 Jul;144(7):886-92 [18645140.001]

[Cites] J Invest Dermatol. 2001 Nov;117(5):1027-35 [11710909.001]

[Cites] Australas J Dermatol. 2002 May;43(2):81-90; quiz, 91-2 [11982563.001]

[Cites] Australas J Dermatol. 2002 Aug;43(3):157-68; quiz 169-70 [12121391.001]

[Cites] Am J Clin Dermatol. 2003;4(2):97-105 [12553850.001]

[Cites] J Eur Acad Dermatol Venereol. 2003 Jan;17(1):100-1 [12602986.001]

[Cites] J Am Acad Dermatol. 2004 Feb;50(2):289-92 [14726890.001]

[Cites] Arch Dermatol. 2004 Oct;140(10):1253-7 [15492189.001]

[Cites] J Med Genet. 1968 Dec;5(4):273-80 [5713638.001]

[Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]

[Cites] J Am Acad Dermatol. 1988 Feb;18(2 Pt 1):369-72 [3346418.001]

[Cites] J R Coll Physicians Lond. 1988 Oct;22(4):240-3 [3230540.001]

[Cites] Br J Dermatol. 1992 Mar;126(3):275-82 [1554604.001]

[Cites] Clin Exp Dermatol. 1993 Mar;18(2):146-7 [8481991.001]

[Cites] J R Soc Med. 1994 Jul;87(7):419-20 [8046733.001]

(PMID = 20462663.001).

[ISSN] 1097-6787

[Journal-full-title] Journal of the American Academy of Dermatology

[ISO-abbreviation] J. Am. Acad. Dermatol.

[Language] ENG

[Grant] United States / Intramural NIH HHS / / Z01 HL002541-13; United States / NCI NIH HHS / CA / R01 CA100907-03; United States / NCI NIH HHS / CA / CA100907-01A1; United States / Intramural NIH HHS / / ZIA HL002541-14; United States / Intramural NIH HHS / / Z01 HL002541-12; United States / NCI NIH HHS / CA / CA100907-03; United States / NCI NIH HHS / CA / R01 CA100907-02; United States / NCI NIH HHS / CA / R01 CA100907-01A1; United States / NCI NIH HHS / CA / CA100907-02; United States / NCI NIH HHS / CA / R01 CA100907-04; United States / NCI NIH HHS / CA / CA100907-04; United States / NCI NIH HHS / CA / R01 CA100907

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ NIHMS234580; NLM/ PMC2947366

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

BACKGROUND: Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mTOR).

METHODS: We conducted a 24-month, nonrandomized, open-label trial to determine whether sirolimus reduces the angiomyolipoma volume in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

Serial magnetic resonance imaging of angiomyolipomas and brain lesions, computed tomography of lung cysts, and pulmonary-function tests were performed.

One year after sirolimus was discontinued, the FEV1 was 62+/-411 ml above the baseline value, the FVC was 346+/-712 ml above the baseline value, and the residual volume was 333+/-570 ml below the baseline value; cerebral lesions were unchanged.

Suppression of mTOR signaling might constitute an ameliorative treatment in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. (ClinicalTrials.gov number, NCT00457808. )

[MeSH-major] Angiomyolipoma / drug therapy. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / complications. Lymphangioleiomyomatosis / complications. Sirolimus / therapeutic use. Tuberous Sclerosis / complications

[MeSH-minor] Adult. Brain / pathology. Female. Humans. Kidney Diseases / pathology. Liver Diseases / pathology. Lung / diagnostic imaging. Lung / physiopathology. Magnetic Resonance Imaging. Male. Middle Aged. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / metabolism. Radiography. Respiratory Function Tests. TOR Serine-Threonine Kinases

Genetic Alliance. consumer health - Lymphangioleiomyomatosis.

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853421 for PMID:18184959 [PharmGKB] .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

Hazardous Substances Data Bank. SIROLIMUS .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2008 Massachusetts Medical Society

[Cites] Arch Neurol. 2000 May;57(5):662-5 [10815131.001]

[Cites] Cancer Control. 2006 Oct;13(4):276-85 [17075565.001]

[Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90 [10823953.001]

[Cites] Transplantation. 2000 May 27;69(10):2085-90 [10852601.001]

[Cites] Am J Respir Crit Care Med. 2001 Aug 15;164(4):661-8 [11520734.001]

[Cites] Radiology. 2001 Sep;220(3):696-706 [11526269.001]

[Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]

[Cites] Ann Pharmacother. 2002 Sep;36(9):1391-5 [12196058.001]

[Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]

[Cites] Eur J Gynaecol Oncol. 2002;23(5):401-4 [12440811.001]

[Cites] Am J Respir Crit Care Med. 2003 Apr 1;167(7):976-82 [12411287.001]

[Cites] Am J Respir Crit Care Med. 2003 May 1;167(9):1287 [12714344.001]

[Cites] Kidney Int. 2003 Sep;64(3):1035-45 [12911554.001]

[Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]

[Cites] Transplantation. 2004 Jul 27;78(2):264-8 [15280688.001]

[Cites] Kidney Int. 2004 Sep;66(3):924-34 [15327383.001]

[Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]

[Cites] Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36 [7663792.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):915-24 [8751400.001]

[Cites] Clin Nephrol. 1998 May;49(5):281-6 [9617489.001]

[Cites] Transplant Proc. 1998 Dec;30(8):3950-1 [9865258.001]

[Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):523-8 [10088622.001]

[Cites] Transplantation. 1999 Apr 15;67(7):1036-42 [10221490.001]

[Cites] Arch Dermatol. 1999 May;135(5):553-7 [10328196.001]

[Cites] J Child Neurol. 2004 Sep;19(9):643-9 [15563009.001]

[Cites] Chest. 2004 Dec;126(6):1867-74 [15596686.001]

[Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]

[Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]

[Cites] J Clin Oncol. 2005 Aug 10;23(23):5294-304 [15998902.001]

[Cites] Am J Respir Crit Care Med. 2006 Jan 1;173(1):105-11 [16210669.001]

[Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]

[Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]

[Cites] AJR Am J Roentgenol. 2006 Jul;187(1):65-72 [16794157.001]

[Cites] Am J Kidney Dis. 2006 Sep;48(3):e27-9 [16931204.001]

[CommentIn] N Engl J Med. 2008 May 1;358(18):1963-4; author reply 1964 [18450609.001]

[CommentIn] N Engl J Med. 2008 Jan 10;358(2):190-2 [18184966.001]

(PMID = 18184959.001).

[ISSN] 1533-4406

[Journal-full-title] The New England journal of medicine

[ISO-abbreviation] N. Engl. J. Med.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00457808

[Grant] United States / NCI NIH HHS / CA / CA103486; United States / NCRR NIH HHS / RR / M01 RR008084; United States / NCI NIH HHS / CA / R21 CA103486-02; United States / NCI NIH HHS / CA / R21 CA103486; United States / NCI NIH HHS / CA / R21 CA103486-01; United States / NCRR NIH HHS / RR / M01 RR08084

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Protein Kinase Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus

[Other-IDs] NLM/ NIHMS116421; NLM/ PMC3398441

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).

Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC) are highly desired to enable detailed investigation of the pathogenesis of these diseases.

Multiple rats and mice have been generated in which a mutation similar to that occurring in TSC patients is present in an allele of Tsc1 or Tsc2.

Unfortunately, these mice do not develop pathologic lesions that match those seen in LAM or TSC.

However, these Tsc rodent models have been useful in confirming the two-hit model of tumor development in TSC, and in providing systems in which therapeutic trials (e.g., rapamycin) can be performed.

Efforts to generate an authentic LAM model are impeded by a lack of understanding of the cell of origin of this process.

Genetic Alliance. consumer health - Lymphangioleiomyomatosis.

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cancer. 2009;8:38 [19527517.001]

[Cites] Hum Mol Genet. 2009 Jul 1;18(13):2378-87 [19357198.001]

[Cites] Genomics. 2001 Dec;78(3):108-12 [11735216.001]

[Cites] Carcinogenesis. 2001 Dec;22(12):2049-52 [11751438.001]

[Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]

[Cites] Am J Hum Genet. 2002 Oct;71(4):750-8 [12192641.001]

[Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]

[Cites] Cancer Res. 2003 May 15;63(10):2675-80 [12750296.001]

[Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]

[Cites] Cancer Res. 2003 Sep 1;63(17):5173-7 [14500340.001]

[Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):349-56 [14566855.001]

[Cites] Diagn Histopathol. 1981 Jan-Mar;4(1):99-110 [7249912.001]

[Cites] J Urol. 1992 Dec;148(6):1932-6 [1433648.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):327-31 [8419937.001]

[Cites] Cancer Res. 1994 May 15;54(10):2633-5 [8168090.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11413-6 [7972075.001]

[Cites] Nat Genet. 1995 Jan;9(1):70-4 [7704028.001]

[Cites] Mol Carcinog. 1995 Sep;14(1):28-36 [7546222.001]

[Cites] Jpn J Cancer Res. 1995 Sep;86(9):828-32 [7591959.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3990-3 [9108092.001]

[Cites] Jpn J Cancer Res. 1997 Mar;88(3):254-61 [9140109.001]

[Cites] Am J Pathol. 1997 Nov;151(5):1477-86 [9358774.001]

[Cites] Cancer Res. 1999 Mar 15;59(6):1206-11 [10096549.001]

[Cites] J Clin Invest. 1999 Sep;104(6):687-95 [10491404.001]

[Cites] Acta Pathol Microbiol Scand. 1954;34(6):554-62 [13206757.001]

[Cites] Curr Mol Med. 2004 Dec;4(8):799-806 [15579026.001]

[Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]

[Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):213-27 [15578690.001]

[Cites] Hum Mol Genet. 2005 Feb 1;14(3):429-35 [15601645.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2474-81 [15781664.001]

[Cites] Hum Mol Genet. 2005 Jul 1;14(13):1839-50 [15888477.001]

[Cites] Cancer Res. 2006 Aug 15;66(16):7934-8 [16912167.001]

[Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):933-44 [16845661.001]

[Cites] Genesis. 2007 Feb;45(2):101-6 [17245776.001]

[Cites] BMC Pharmacol. 2007;7:14 [17986349.001]

[Cites] Mol Cell Biol. 2008 May;28(9):2971-9 [18316403.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9250-5 [18587048.001]

[Cites] Hum Mol Genet. 2009 Jun 15;18(12):2166-76 [19321600.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8762-7 [11438694.001]

(PMID = 20235887.001).

[ISSN] 1557-8585

[Journal-full-title] Lymphatic research and biology

[ISO-abbreviation] Lymphat Res Biol

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA120964; United States / NINDS NIH HHS / NS / P01 NS024279; United States / NINDS NIH HHS / NS / R01 NS031535; United States / NINDS NIH HHS / NS / R37 NS031535

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases

[Number-of-references] 39

[Other-IDs] NLM/ PMC2883495

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetics and molecular biology of tuberous sclerosis complex.

Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys.

Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes.

Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 4E-BP1, resulting in uncontrolled cell growth and tumourigenesis.Despite recent promising genetic, diagnostic, and therapeutic advances in Tuberous Sclerosis Complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality.

In this review we will discuss and analyse all the important findings in the molecular pathogenesis of Tuberous Sclerosis Complex, focusing on genetics and the molecular mechanisms that define this multisystemic disorder.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]

[Cites] Hum Mol Genet. 2001 Dec 1;10(25):2889-98 [11741832.001]

[Cites] Brain Dev. 2001 Nov;23(7):698-704 [11701281.001]

[Cites] Brain Dev. 2001 Nov;23(7):502-7 [11701245.001]

[Cites] Nat Med. 2001 Oct;7(10):1159-62 [11590442.001]

[Cites] Am J Hum Genet. 2001 Sep;69(3):493-503 [11468687.001]

[Cites] Hum Genet. 2000 Aug;107(2):97-114 [11030407.001]

[Cites] Nat Cell Biol. 2000 May;2(5):281-7 [10806479.001]

[Cites] Nat Cell Biol. 1999 Dec;1(8):500-6 [10587646.001]

[Cites] J Biol Chem. 2000 Jun 9;275(23):17566-70 [10764727.001]

[Cites] Dev Biol. 2000 May 15;221(2):404-18 [10790335.001]

[Cites] Am J Hum Genet. 1999 Dec;65(6):1790-5 [10577937.001]

[Cites] J Immunol. 2000 Jan 1;164(1):231-9 [10605016.001]

[Cites] Hum Mutat. 1999;14(5):412-22 [10533067.001]

[Cites] Nature. 1999 Nov 4;402(6757):30-1 [10573413.001]

[Cites] Nat Cell Biol. 1999 Aug;1(4):207-14 [10559918.001]

[Cites] Nat Cell Biol. 1999 Aug;1(4):193-9 [10559916.001]

[Cites] Mutat Res. 2006 Sep;613(1):10-6 [16713332.001]

[Cites] J Biol Chem. 2006 Mar 31;281(13):8313-6 [16464865.001]

[Cites] Med Res Rev. 2006 Mar;26(2):160-80 [16329102.001]

[Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]

[Cites] Hum Mol Genet. 2006 Jan 15;15(2):287-97 [16339216.001]

[Cites] J Cell Biol. 2005 Aug 1;170(3):379-89 [16043512.001]

[Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):818-26 [15963462.001]

[Cites] FASEB J. 2005 Jul;19(9):1202-4 [15851513.001]

[Cites] Am J Pathol. 2005 Jul;167(1):107-16 [15972957.001]

[Cites] Eur J Hum Genet. 2005 Jun;13(6):731-41 [15798777.001]

[Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]

[Cites] Semin Cell Dev Biol. 2005 Feb;16(1):29-37 [15659337.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):667-72 [15647351.001]

[Cites] J Cell Biol. 2004 Dec 20;167(6):1171-82 [15611338.001]

[Cites] Eur J Hum Genet. 2005 Jan;13(1):59-68 [15483652.001]

[Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]

[Cites] J Biol Chem. 2004 Nov 19;279(47):48707-15 [15355997.001]

[Cites] Am J Hum Genet. 1999 Jul;65(1):39-49 [10364515.001]

[Cites] Am J Hum Genet. 1999 Apr;64(4):986-92 [10090883.001]

[Cites] Cell. 1999 Jun 25;97(7):865-75 [10399915.001]

[Cites] Hum Mol Genet. 1997 Oct;6(11):1991-6 [9302281.001]

[Cites] Science. 1999 Sep 24;285(5436):2126-9 [10497130.001]

[Cites] Eur J Immunogenet. 1999 Feb;26(1):1-3 [10068907.001]

[Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]

[Cites] J Med Genet. 1999 Apr;36(4):285-9 [10227394.001]

[Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]

[Cites] Nat Genet. 1994 Feb;6(2):193-6 [8162074.001]

[Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]

[Cites] Cell. 1994 Jun 17;77(6):881-94 [8004675.001]

[Cites] AJNR Am J Neuroradiol. 1995 Jan;16(1):149-55 [7900584.001]

[Cites] J Med Genet. 1995 Feb;32(2):102-4 [7760316.001]

[Cites] Cell. 2001 May 4;105(3):345-55 [11348591.001]

[Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6144-9 [11344272.001]

[Cites] Mol Cell. 2001 Apr;7(4):823-32 [11336705.001]

[Cites] Br J Ophthalmol. 2001 Apr;85(4):420-3 [11264130.001]

[Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]

[Cites] Biochim Biophys Acta. 2000 Nov 15;1502(3):495-507 [11068191.001]

[Cites] Cell. 1999 Feb 19;96(4):529-39 [10052455.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15629-34 [9861021.001]

[Cites] Cell. 1998 Jun 26;93(7):1183-93 [9657151.001]

[Cites] Hum Mol Genet. 1997 Dec;6(13):2265-9 [9361032.001]

[Cites] Am J Hum Genet. 1997 Oct;61(4):843-51 [9382094.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3990-3 [9108092.001]

[Cites] Jpn J Cancer Res. 1997 Mar;88(3):254-61 [9140109.001]

[Cites] Am J Pathol. 1997 Nov;151(5):1477-86 [9358774.001]

[Cites] Hum Mol Genet. 1997 Nov;6(12):2155-61 [9328481.001]

[Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]

[Cites] J Med Genet. 1997 Mar;34(3):256-60 [9132502.001]

[Cites] EMBO J. 1996 Dec 2;15(23):6584-94 [8978685.001]

[Cites] Nat Genet. 1995 Jan;9(1):70-4 [7704028.001]

[Cites] Am J Ophthalmol. 1995 Mar;119(3):318-24 [7872393.001]

[Cites] Dev Med Child Neurol. 1994 Jan;36(1):50-6 [8132114.001]

[Cites] J Med Genet. 1993 Jan;30(1):41-3 [8423606.001]

[Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9231-5 [2123553.001]

[Cites] Hum Genet. 1991 Nov;88(1):85-90 [1959929.001]

[Cites] Ann N Y Acad Sci. 1991;615:50-7 [2039167.001]

[Cites] Am J Hum Genet. 1988 Oct;43(4):355-63 [3052049.001]

[Cites] J Med Genet. 1989 Jan;26(1):28-31 [2918523.001]

[Cites] BJU Int. 2004 Oct;94(6):853-7 [15476522.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94 [15342917.001]

[Cites] J Biol Chem. 2004 Aug 20;279(34):35664-70 [15175323.001]

[Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]

[Cites] Hum Mutat. 2004 Jan;23(1):99 [14695542.001]

[Cites] Cancer Res. 2003 Dec 1;63(23):8451-60 [14679009.001]

[Cites] Pediatr Neurol. 2003 Nov;29(5):404-9 [14684235.001]

[Cites] J Biol Chem. 2003 Dec 19;278(51):51372-9 [14551205.001]

[Cites] Ann Hum Genet. 2003 Nov;67(Pt 6):495-503 [14641237.001]

[Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]

[Cites] Gene. 2003 Nov 27;320:145-54 [14597398.001]

[Cites] Mutat Res. 2008 Mar-Apr;658(3):234-46 [18291711.001]

[Cites] Ann Neurol. 2008 Apr;63(4):444-53 [18389497.001]

[Cites] BMC Med Genet. 2008;9:10 [18302728.001]

[Cites] BMC Dermatol. 2008;8:1 [18226258.001]

[Cites] Mol Cancer. 2008;7:10 [18218111.001]

[Cites] Mol Cell. 2008 Mar 14;29(5):541-51 [18342602.001]

[Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]

[Cites] Neurosignals. 2006-2007;15(5):217-27 [17389815.001]

[Cites] Biochem Biophys Res Commun. 2007 Sep 14;361(1):218-23 [17658474.001]

[Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]

[Cites] Mol Cell Neurosci. 2007 May;35(1):100-8 [17355907.001]

[Cites] Oncogene. 2007 Jan 25;26(4):521-31 [16862180.001]

[Cites] J Biol Chem. 2006 Dec 29;281(52):40242-51 [17077083.001]

[Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]

[Cites] Cell. 2006 Sep 8;126(5):955-68 [16959574.001]

[Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]

[Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]

[Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):592-6 [12773162.001]

[Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):587-91 [12773161.001]

[Cites] J Biol Chem. 2003 Apr 18;278(16):13663-71 [12582162.001]

[Cites] Psychol Med. 2003 Feb;33(2):335-44 [12622312.001]

[Cites] J Biol Chem. 2003 Jan 24;278(4):2089-92 [12468542.001]

[Cites] J Biol Chem. 2002 Nov 15;277(46):44180-6 [12226091.001]

[Cites] Radiology. 2002 Nov;225(2):451-6 [12409579.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6 [12271141.001]

[Cites] Am J Hum Genet. 2002 Oct;71(4):750-8 [12192641.001]

[Cites] Mol Cell. 2002 Jul;10(1):151-62 [12150915.001]

[Cites] Genetics. 2002 Jul;161(3):1053-63 [12136010.001]

[Cites] Brain. 2002 Jun;125(Pt 6):1247-55 [12023313.001]

[Cites] Genes Dev. 2001 Jun 1;15(11):1383-92 [11390358.001]

[Cites] J Biol Chem. 2002 Apr 19;277(16):13973-82 [11830582.001]

(PMID = 19506736.001).

[ISSN] 1389-2029

[Journal-full-title] Current genomics

[ISO-abbreviation] Curr. Genomics

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Other-IDs] NLM/ PMC2691673

[Keywords] NOTNLM ; Tuberous sclerosis / genetics / germ-line mosaicism / hamartin / multifactorial disease / mutations / rapamycin. / tuberin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ocular surface temperature in central retinal vein occlusion: Preliminary data.

PURPOSE: To compare ocular surface temperature (OST) measures in patients with central retinal vein occlusion (CRVO) and controls.

Ischemic CRVO eyes showed lower temperatures than nonischemic ones.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28221516.001).

[ISSN] 1724-6016

[Journal-full-title] European journal of ophthalmology

[ISO-abbreviation] Eur J Ophthalmol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Thermal sensitivity of oxidative phosphorylation in rat heart mitochondria: Does pyruvate dehydrogenase dictate the response to temperature?

To identify the most temperature-sensitive steps in the energy production pathways, we measured the thermal sensitivity of mitochondrial oxidative phosphorylation (OXPHOS), as well as that of the individual steps in this process in rat heart mitochondria.

OXPHOS measured in the presence of pyruvate+malate as substrates have an unusually high thermal sensitivity between 5 and 15°C.

Furthermore, the thermal sensitivity of OXPHOS correlates with the thermal sensitivity of pyruvate dehydrogenase between 5 and 35°C.

Pyruvate dehydrogenase is a potential control point for pyruvate-supported mitochondrial respiration below physiological temperature in rat heart.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2009 Elsevier Ltd. All rights reserved.

(PMID = 28799912.001).

[ISSN] 0306-4565

[Journal-full-title] Journal of thermal biology

[ISO-abbreviation] J. Therm. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of tear evaporation from ocular surface by functional infrared thermography.

PURPOSE: A novel technique was developed to measure tear evaporation and monitor its variation with respect to time, for the studying of ocular physiology based on dynamic functional infrared thermography and the first law of thermodynamics using the measured ocular surface temperatures (OSTs).

This is a noninvasive, noncontact temperature measuring method that is widely applied in the field of biomedicine.

For each thermal sequence, the ocular region was selected and warped to a standard form.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 American Association of Physicists in Medicine.

(PMID = 28525014.001).

[ISSN] 2473-4209

[Journal-full-title] Medical physics

[ISO-abbreviation] Med Phys

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Convection / Evaporation / Eyes / Heat transfer / Lipids / Medical imaging / Physiology / Skin / Thermal imaging / Thermography / Thin films / Visual imaging / biomedical measurement / biomedical optical imaging / biothermics / evaporation / image sequences / infrared / infrared imaging / medical image processing / tear / thermodynamics / thermography

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Physical effects of mechanical design parameters on photon sensitivity and spatial resolution performance of a breast-dedicated PET system.

PURPOSE: This study aims to address design considerations of a high resolution, high sensitivity positron emission tomography scanner dedicated to breast imaging.

METHODS: The methodology uses a detailed Monte Carlo model of the system structures to obtain a quantitative evaluation of several performance parameters.

Special focus was given to the effect of dense mechanical structures designed to provide mechanical robustness and thermal regulation to the minuscule and temperature sensitive detectors.

RESULTS: For the energies of interest around the photopeak (450-700 keV energy window), the simulation results predict a 6.5% reduction in the single photon detection efficiency and a 12.5% reduction in the coincidence photon detection efficiency in the case that the mechanical structures are interspersed between the detectors.

However for lower energies, a substantial increase in the number of detected events (approximately 14% and 7% for singles at a 100-200 keV energy window and coincidences at a lower energy threshold of 100 keV, respectively) was observed with the presence of these structures due to backscatter.

The number of photon events that involve multiple interactions in various crystal elements is also affected by the presence of the structures.

For photon events involving multiple interactions among various crystal elements, the coincidence photon sensitivity is reduced by as much as 20% for a point source at the center of the field of view.

CONCLUSIONS: Mechanical structures can have a considerable effect on system sensitivity, especially for systems processing multi-interaction photon events.

Various mechanical structure designs are currently under evaluation in order to achieve optimum trade-off between temperature stability, accurate detector positioning, and minimum influence on system performance.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 American Association of Physicists in Medicine.

(PMID = 28525006.001).

[ISSN] 2473-4209

[Journal-full-title] Medical physics

[ISO-abbreviation] Med Phys

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Crystal structure / Image detection systems / Image reconstruction / Image sensors / Medical imaging / Monte Carlo methods / Monte Carlo simulations / Ozone / Photodetectors (including infrared and CCD detectors) / Photons / Position sensitive detectors / Positron emission tomography / Positron emission tomography (PET) / Spatial resolution / biological organs / breast imaging / gynaecology / high resolution / photodetectors / photon sensitivity / positron emission tomography / positron emission tomography (PET) / spatial resolution

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical presentation and diagnosis of tuberous sclerosis complex in infancy.

The age-dependent nature of the characteristic features of tuberous sclerosis complex has historically presented challenges for the diagnosis in infancy.

Although the increasing availability of neuroimaging and genetic testing has facilitated the diagnosis in neonates and infants, there are few reports describing how tuberous sclerosis complex presents in this age group.

We performed a retrospective review of children diagnosed with tuberous sclerosis complex during the first year of life, compiling their clinical features at presentation and diagnosis, seizure history, and imaging findings.

We identified 41 infants diagnosed with tuberous sclerosis complex before age 1 year.

Five infants (12%) had a family history of tuberous sclerosis complex.

A definitive diagnosis of tuberous sclerosis complex was accomplished antenatally in 4 patients, whereas the rest were diagnosed at a median age of 2 months.

Neuroimaging resulted in a definitive diagnosis of tuberous sclerosis complex in 95% of patients.

The diagnosis of tuberous sclerosis complex in infancy is aided by a high index of suspicion and timely access to neuroimaging.

Early diagnosis of tuberous sclerosis complex may be essential to the success of future therapies by providing a window of opportunity for their use.

[MeSH-major] Autistic Disorder / pathology. Heart Neoplasms / pathology. Rhabdomyoma / pathology. Spasm / pathology. Tuberous Sclerosis / diagnosis. Tuberous Sclerosis / pathology

[MeSH-minor] Brain / pathology. Diagnosis, Differential. Female. Humans. Hypopigmentation / complications. Hypopigmentation / pathology. Infant. Infant, Newborn. Infant, Newborn, Diseases. Magnetic Resonance Imaging. Male. Prenatal Diagnosis. Retrospective Studies. Syndrome. Tomography, X-Ray Computed

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18230839.001).

[ISSN] 0883-0738

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of mutational analysis in diagnosis of tuberous sclerosis complex.

We describe three cases in whom identification of a disease-causing mutation in the TSC1 or TSC2 gene preceded the appearance or detection of symptoms sufficient for a clinical diagnosis of tuberous sclerosis complex (TSC).

We suggest that genetic testing be given a more prominent role in the evaluation of individuals with a family history of TSC or symptoms suggestive of TSC and propose that diagnostic criteria be revised to include genetic testing.

[MeSH-major] DNA Mutational Analysis. Tuberous Sclerosis / diagnosis

Genetic Alliance. consumer health - Tuberous sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19250385.001).

[ISSN] 1399-0004

[Journal-full-title] Clinical genetics

[ISO-abbreviation] Clin. Genet.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Denmark

[Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex.

We report a randomized, double-blind, controlled, crossover trial investigating the response to oral melatonin using two dose regimens in patients with sleep disorders associated with tuberous sclerosis complex.

Eight outpatients with tuberous sclerosis complex and sleep disorder received either 5 or 10 mg of melatonin.

Sleep latency, total sleep time, number of awakenings, and seizure frequency were recorded in sleep and seizure diaries.

No evidence of a dose effect between 5 and 10 mg was seen with respect to any outcome measure. (The 5 mg results are given first: sleep latency, 86 and 76 minutes; total sleep time, 8 hours, 57 minutes and 9 hours, 4 minutes; and sleep fragmentation, 0.8 and 1.0).

We propose that an initial trial of 5 mg melatonin is worth considering in patients with tuberous sclerosis complex and sleep disorder.

[MeSH-major] Antioxidants / therapeutic use. Melatonin / therapeutic use. Sleep Wake Disorders / drug therapy. Sleep Wake Disorders / etiology. Tuberous Sclerosis / complications

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Antioxidants.

MedlinePlus Health Information. consumer health - Sleep Disorders.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15791928.001).

[ISSN] 0883-0738

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antioxidants; JL5DK93RCL / Melatonin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

METHODS: Pts with clear-cell mRCC treated with sunitinib from June 1, 2004, to October 5, 2007, were retrospectively identified.

CT scan images were re-reviewed from baseline, at the time of maximal tumor burden shrinkage (TS), at time of disease progression and at time of last assessment prior to death.

TB and percent TS were measured per RECIST criteria.

Sites of metastases included: lung (87%), mediastinal lymph nodes (52%), retroperitoneal lymph nodes (36%), adrenal (29%), bone (38%), liver (22%), pancreas (14%), kidney (7%), and brain (6%).

Overall response rate was 52% and 87% had some degree of TS.

In multivariable analysis, disease confined to above the diaphragm (p = 0.03) and total TB <13cm (p = 0.09) prior to sunitinib were independent positive predictors of PFS.

Increased TS while on sunitinib was also prognostic for OS (p < 0.001).

At time of disease progression (PD), tumor location and pattern of progression were not associated with OS.

At the time of last assessment prior to death, median TB was 23.9 cm, significantly higher (p < 0.001) than in pts still alive (median TB 14.4 cm).

CONCLUSIONS: Tumor burden shrinkage and tumor burden at time of disease progression are associated with overall survival in pts with mRCC treated with sunitinib.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962954.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Understanding the effect of these perturbations on the delivered dose will help in determination of appropriate treatment structure volume (TS) expansions to ensure adequate coverage.

Using a simple dose calculation program, the simulated dose spots were used to create a treatment plan to deliver a uniform 75 Gy dose to a TS within a water phantom.

To determine effects of steering uncertainties, small random magnetic field perturbations (ΔB⩽±0.1%) were added to the steering parameters used to deliver a uniform TS dose.

Variations in the dose delivered to the TS and an adjacent critical structure (CS) due to magnetic steering uncertainties were determined.

This included determination of dose hot and cold spots in the TS, and changes to the dose volume histogram (DVH) of the TS and CS.

RESULTS: The TS volume receiving 95% of the prescribed dose decreased by as much as 7% and the maximum TS dose increased by as much as 13% due to random magnetic steering uncertainties.

The maximum possible dose hot and cold spots created by deliberately moving adjacent spots in the TS were calculated to be 187% and 52% of the prescription dose, respectively.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2007 American Association of Physicists in Medicine.

(PMID = 28493560.001).

[ISSN] 2473-4209

[Journal-full-title] Medical physics

[ISO-abbreviation] Med Phys

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Keywords] NOTNLM ; Drug delivery / Magnetic fields / Magnetic materials / Magnets / Medical treatment planning / Monte Carlo methods / Proton therapy / Protons

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Colorectal cancer tumors were prospectively analyzed with a predefined set of 11 molecular targets, including: KRas and PI3K mutations, EGFR amplification (FISH), and ERCC-1, TS, TP expression by IHC.

ERCC-1 was positive in 5/78 (6.4%) and TS was positive in 47%.

In this last group for whom the response to multiple agents is known, the panel predictive the most effective treatment in 14 of 24 cases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963192.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impacts of microRNA-215 on cell proliferation and chemotherapy resistance in colon cancer and osteosarcoma.

METHODS: miR-215 was ectopically expressed by transient transfection in both human colon cancer cell lines and osteosarcoma cell lines.

The impact of miR-215 on cell proliferation, cell cycle control, chemosensitivity and down stream targets were characterized.

The expression of miR-215 in colorectal cancer specimens and normal adjacent tissues was quantified by real time-qRT-PCR analysis.

RESULTS: In this study, we discovered that miR-215 down-regulates the expression of both dihydrofolate reductase (DHFR) and thymidylate synthase (TS), two of the most important chemotherapeutic targets, in human osteosarcoma U-2 OS and colon cancer HCT-116 (wt-p53) cell lines.

Cells with elevated miR-215 expression are more resistant to DHFR inhibitor methotrexate (MTX) or TS inhibitor Tomudex (TDX) treatment.

Ectopically over-expressing miR-215 triggers reduced cell proliferation and increased G2 arrest, at least in part, through the induction of p53 and p21. miR-215 transfected cells with reduced proliferating phenotype were resist to MTX or TDX treatment due to deceased cell cycle in S phase.

The expression of endogeneous miR-215 was highly elevated in CD133^+/HI CD44^+/HI colon cancer stem cells compared to CD133^- CD44^- colon cancer cells, suggesting that tumor stem cells may be avoiding cellular and DNA damage caused by chemotherapy with a reduced proliferating phenotype mediated by certain miRNAs such as miR-215.

The elevated expression of miR-215 in colon cancer stem cells with slow proliferation rate and resistance to chemotherapy further supports the role of miR-215 in cell proliferation and chemotherapy resistance.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961866.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: 77 stage II/III rectal patients were genotyped using direct sequencing (TS VNTR) and SNAPshot (DPYD, EGFR) techniques.

We have studied Thymidylate synthetase (TS VNTR; high expression haplotypes: TSER 2R/3R, 3C/3G, 3G/3G and low expression: TSER 2R/2R, 2R/3C, 3C/3C; TS 1494del6: associated to a better efficay of 5Fu), dihydropyrimidine dehydrogenase (DPYD; DPYD*2 associated to worse toxicity), EGFR (CA repeats in intron 1: 16/16 associated to worse efficacy) polymorphisms.

50 patients (64.9%) and 27 (35.1%) had low and high expression genotype for TS respectively. pCR (TRG1) was obtained in 24 patients (31,6%) and microscopic foci (TRG2) in 14 (18,2%), TRG 3-4 in 38 (49,3%), and 1 patient had no response (TRG5).

We haven't found a statistically significant relationship between TRG1 and TS status, or any other biomarker studied.

CONCLUSIONS: Biomarkers EGFR (intron 1 CA repeats), TS (TS 1494del6, TS VNTR) and DPYD in blood samples, are not good enough to predict response to RQ in rectal cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964541.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Excision repair cross-complementing group 1 (ERCC1), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are reportedly related to outcome of advanced gastric cancer (AGC) patients (pts) treated with IP or 5-FU.

Efficacy analyses are performed to evaluate the status of ERCC1, TS, DPD and 5 biomarkers related to anticancer drug sensitivity in first-line pts treated with IP, S-1, or 5-FU monotherapy under controlled conditions.

Using laser-captured microdissection and real-time RT-PCR, we analyzed mRNA expression of ERCC1, TS, DPD in paraffin-embedded specimens.

Expression levels of each gene were categorized into low and high values at each median.

RESULTS: The subjects with available tissue for analysis were representative of all randomized pts; 232 samples were assessable for TS, 168 for DPD, and 235 for ERCC1.

Pts with high TS showed worse progression-free survival (PFS) compared with those with low TS (hazard ratio (HR):1.26 [95%CI: 0.97-1.63]) in all pts; there was no difference in PFS between DPD and ERCC1 expression level.

IP showed better PFS than S-1 in low DPD (HR: 0.57 [95%CI: 0.32-1.01]) but not in high DPD (HR: 1.24 [95%CI: 0.76-2.04]); there was no clear difference in PFS between pts treated with IP and S-1 regardless of TS and ERCC1 expression status.

CONCLUSIONS: This large analysis showed the prognostic value of TS status in AGC pts and the predictive value of DPD status for IP and S-1 as first-line treatment.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962991.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

These structures which are related with the malignant behavior are actively investigated as immunotherapeutic targets.

The objective of this work was to describe the abnormal expression of ppGalNAc-Ts in colon cancer comparing its relationship with incomplete O- glycosylated antigens.

METHODS: We studied the gene expression of ppGalNAc-Ts in colon cell lines by RT-PCR assays.

RESULTS: We found that ppGalNAc-T6 (an enzyme usually restricted to normal placenta, trachea, brain, and pancreas) is expressed by colon cancer cell lines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964510.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial.

METHODS: Eligible pts included: histologically confirmed advanced NSCLC, previous treatment with platinum-based therapy and a taxane, no more than 2 prior regimens, measurable disease, Zubrod performance status ≤ 2.

Pts were classified by taxane-sensitivity status: taxane sensitive (TS) (progression >90 days after taxane) or taxane resistant (TR) (progression during or ≤90 days after taxane).

TREATMENT: E7389 1.4 mg/m² intravenously over 1-2 minutes on day 1 and 8 of a 21 day schedule until disease progression or unacceptable toxicity.

There were 3 (15%) objective responses (7.2+, 8.5+, 10.6 mo) of 20 TS pts; and no response of 21 TR pts.

Stable disease rate was 60% and 24% in TS and TR pts. respectively.

Median progression free survival (PFS) is 6.3 mos TS pts.

Median number of cycles (range): TS 4 (1-14); TR 2 (1-7).

CONCLUSIONS: E7389 was well tolerated with encouraging objective response, PFS and disease control rate in the TS cohort.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962869.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Aim of this study was to identify potential predictors of tumor shrinkage (TS) in a retrospective series of pts receiving preoperative anthracycline-based CT for operable BC.

Association between clinico-biological factors and clinico-radiological TS (by caliper and MRI) was assessed.

TS was calculated as the difference between the maximum tumor diameter at baseline and the maximum tumor diameter after preoperative CT/ the maximum tumor diameter at baseline x 100.

RESULTS: In univariate analysis, the following variables were associated with clinical TS: high MIB-1 [Odd ratio (OR) 2.6, p = 0.03], type of taxane (docetaxel vs paclitaxel: OR 0.3, p = 0.01) and number of cycles of CT (> 4 vs ≤ 4: OR 9.2, p < 0.0001).

In multivariate analysis, number of cycles of CT was the only independent predictor of clinical TS (OR = 9.2, p = 0.05).

In univariate analysis, the following variables were associated with MRI TS: high MIB-1 (OR 2.4, p = 0.06), tumor size (≥ 40 mm vs < 40 mm: OR 5.6, p 0 0.01), taxane CT (yes vs no: OR 4.3, p = 0.02) and number of cycles of CT (> 4 vs ≤ 4: OR 4.4, p = 0.002).

In multivariate analysis, high MIB-1 was the only independent predictor of MRI TS (OR = 3.7, p = 0.03).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964680.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer.

Analyzing TS as a continuous variable (TS-CV) has been suggested as a more robust indicator of efficacy.

Measures of TS at baseline and 8 wks were transformed and represented as a logarithm of the sum of the longest diameters.

Groups were compared using Wilcoxon rank-sum test.

RESULTS: In PA1, TS was significantly decreased in the Gem arm (mean d-LTS 0.087 on MMPI vs. -0.066 on Gem; p<0.0001), in keeping with the OS benefit (p<0.001).

In PA3, for all patients, decrease in TS was significantly larger for the combination arm (mean d- LTS -0.148 on combination vs. -0.114 on Gem; p=0.04), consistent with the OS benefit (p=0.038).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962325.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TS-1 in patients with capecitabine-resistant breast cancer.

: 1103 Background: TS-1 is a novel oral anticancer drug, composed of tegafur, gimestat and otastat potassium in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-Fuorouracil.

To evaluate the efficacy and safety of TS-1 in patients with capecitabine-resistant metastatic breast cancer (MBC).

METHODS: Forty patients with MBC who failed capecitabine-based chemotherapy, received TS-1 (100 mg/m²) at four centers.

Resistance to capecitabine was defined as either progression of disease during treatment, failure to achieve regression of disease after at least four courses, or rapid recurrence after completion of therapy.

Ten pts (25 %) achieved a partial response, 12 patients (30 %) patients had stable disease, and 18 (45 %) progressive disease.

The median time to disease progression was 26.6 weeks.

7 pts experienced serious TS-1- related gastrointestinal disorder requiring dose modifications in 3 pts and treatment discontinuation in 4 pt.

Further, interestingly, 6 of the 40 patients (15.0%) who received TS-1 did hand-foot syndrome (HFS), although 20 of the 40 patients (50.0%) who had received capecitabine, developed HFS.

CONCLUSIONS: This study confirms that TS-1 achieves a high tumor control rate in pretreated MBC pts and is active in patients with capecitabine-resistant breast cancer.

TS-1 should be considered the reference treatment in this setting based on consistently high efficacy and good tolerability.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962169.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We included expression of P53, SMAD4, thymidylate synthetase (TS) and hTERT, mutations of KRAS and BRAF, microsatellite instability (MSI) and 18qLOH.

METHODS: 1,564 formalin fixed paraffin embedded tissue blocks were prospectively collected and DNA from normal and tumor tissue was extracted after macrodissection.

High P53, TS and hTERT expression and SMAD4 loss were assessed by immunohistochemistry.

KRAS exon 2 and BRAF exon 15 mutations were analyzed by allele specific real time PCR.

An interaction test for differences between marker prognostic value for SII and SIII was significant for MSI (p=0.04) and 18qLOH (p=0.04) in SII.

The possibility that the stages represent different diseases, rather than sequential steps in the evolution of a single disease, needs to be considered.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961825.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC).

METHODS: Proteins studied by validated IHC on Benchmark XT were thymidylate synthase (TS), excision repair cross complementing-1 (ERCC1), glycinamide ribonucleotide formyl transferase (GARFT), and folylpolyglutamate synthetase (FPGS).

One hundred fifty-eight SNPs were genotyped for TS, FPGS, γ-glutamyl hydrolase (GGH), methylene tetrahydrofolate reductase (MTHFR), folate receptor- α (FR-α), solute carrier 19A1 (SLC19A1) and adjacent regions.

RESULTS: Of 408 tissue samples (from 908 enrolled pts) available for IHC, 336 samples were assayed for > 1 assay target.

The IHC analyses showed improved OS in the EC arm relative to the PC arm for patients with low TS_nuclear (12.9 vs 7.5 month, p < 0.001, interaction p value = 0.017).

There was no differential treatment effect within the PC arm for low vs. high TS.

High vs low ERCC1 levels did not predict outcome following C exposure.

CONCLUSIONS: Pharmacogenomic analyses of tumor samples show that low TS_nuclear expression correlates with OS in the EC arm.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962831.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e15117 Background: Retrieval of 12 lymph nodes (LN) is a current benchmark in colorectal cancer (CRC) resections according to the National Quality Forum (NQF).

Series of multiple institutions contain variability in surgical and pathologic techniques for lymph node retrieval.

Statview and SAS software analyzed 1)Overall survival (OS) and association with finding >12LN; 2)Number of LN identified and impact on AJCC tumor stage (TS) and overall survival; 3)Number of LN and WHO tumor grade (TG) with OS; 4)The impact of number of positive LN on OS.

RESULTS: Our mean LN found (14.75) is higher than the 12 recommended by the NQF and is not significantly associated with OS regardless of AJCC TS(p=0.06).

The mean LN per TS was I=13.4(N=41)/II=16.3(N=56)/ III=14.3(N=38)/IV 14.2(N=22).

Number of LN identified was not statistically significant in predicting TS(p=0.42) or OS(p=0.24).

WHO TG is significantly associated to decreased OS, but only in AJCC TS II/III/IV and not stage I (Ip>0.05/IIp=0.008/ IIIp=0.01/IVp=0.025).

Higher number of positive LN was associated with lower OS (per each +LN, survival decreases by 0.15 months p=0.001) Conclusions: Contrary to multicenter studies, total number of LN identified does not impact AJCC TS or OS.

This suggests that the tumor biology is more indicative of OS rather than host response (reactive lymphoid tissue) to the tumor.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960844.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer.

: 7521 Background: In non-small cell lung cancer (NSCLC) baseline thymidilate synthase (TS) levels are higher in squamous cell carcinoma (SCC) compared to adenocarcinoma (AC) and randomized clinical trials have shown a selective benefit for patients with non-squamous histology treated with pemetrexed, a TS-inhibiting agent.

TS expression in undifferentiated large cell carcinoma (LCC) is unknown.

METHODS: TS expression at both mRNA (using tissue microdissection and qRT-PCR) and protein (through immunohistochemistry, IHC) levels was tested in 34 surgically resected LCC (stage I=20,II=6,IIIa=8) and compared with TS expression in surgical cases of SCC (n= 31) and AC (n=40).

In addition other comparisons were made: a) TS protein expression with Ki-67 index;.

b) TS mRNA and E2F1 transcription factor mRNA;.

c) in all histotypes TS protein level with desmocollin-3 (DSC-3) immunostaining, a marker of squamous cell differentiation.

TS expression level was assessed in a group of patients (n=22) with cytological diagnosis of NSCLC-NOS (not otherwise specified) and compared with TS data in tissue specimens obtained through subsequent bronchial biopsy or surgical resection.

RESULTS: Significantly higher median TS levels in LCC compared to AC (p<0.001 for both mRNA and protein values) and SCC compared to AC (p=0.002 mRNA, p<0.001 protein) were detected.

A strong correlation between TS mRNA and protein levels were found (p<0.001) in SCC and AC, but not in LCC.

TS and both Ki-67 and E2F1 were significantly correlated in AC and SCC (p=0.003 and p=0.05, respectively), but in LCC no correlation was found.

In LCC, significantly higher TS levels were observed in DSC3-positive compared to DSC3-negative tumors (p=0.02).

A significant correlation between TS IHC scores in matched cytological and corresponding tissue specimens was observed (p<0.001).

CONCLUSIONS: This study demonstrates and confirms the: a) differential expression of TS among the NSCLC histotypes;.

b) lack of DSC-3 immunoreactivity in LCC is associated with lower TS expression;.

c) assessment of TS by IHC in cytological specimens correlates with the corresponding tissue TS expression.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963288.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: The following genetic polymorphisms were analysed: glutathione S-transferase (GSTP1-Ile105Val, GSTT1 and GSTM1 deletion), TYMS (TS-5´UTR 2R/3R; TS-5´G/C; TS-3´UTR 6-bp deletion), MTHFR 1298A>C, UGT1A1, ERCC1, XPD.

Univariate analysis (Fisher´s exact test for response; log-rank test for TTP and OS) was performed to examine associations between polymorphisms and clinical outcome.

M/F: 50/22. Risk according to Köhne classification was low (52.8% of pts), intermediate (26.4%) and high (8.3%).

Heterozygous and homozygous GSTP-105Val showed a significant superior response rate (80%) compared to only 40% in pts harbouring the GSTP1-105Ile/Ile genotype (p = 0.008, Fisher´s exact test).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961864.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TS and MTHFR gene polymorphisms in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head or neck (SCCHN) treated with pemetrexed (P) and bevacizumab (B).

: e17011 Background: P inhibits multiple enzymes in folate metabolism.

We examined polymorphisms in thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) in patients with SCCHN treated in a phase II clinical trial with P and B (ASCO 2008; A6069).

Primary endpoint was time to progression (TTP).

Polymorphisms examined were MTHFR (C677T, A1298C and G1793A) and TS (TS2R3R, TSG2RG and TSmut6).

The TS promoter repeat and promoter SNP polymorphisms and the 3' untranslated region 6 bp deletion polymorphism were determined using published methods to detect PCR product size and RFLP-PCR assays respectively.

For the MTHFR polymorphism C677T, there was a trend towards decreased disease control rate (DCR) (CR/PR/SD) (p = 0.058, Jonckheere-Terpstra trend test) and worse TTP (p = 0.04) transitioning from variant CC to CT to TT; comparing TT genotype versus CT and CC combined, pts with TT had inferior DCR (p = 0.03) and TTP (p = 0.0003); homozygotes with TT had a median TTP of 2.6 months (mo) 95% CI (1.4, NA) versus 5.6 mo (4.2, 11.4) for pts with CT or CC variants.

The MTHFR G1793A and TS polymorphisms did not impact DCR, TTP or overall survival.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961740.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 2569 Background: A principal determinant of the therapeutic index with capecitabine-based treatment is the grade of thymidine phosphorylase (TP) activity in malignant tissue.

On the basis of the time-dependency and transiency for this upregulation we performed a phase I study of capecitabine in combination with weekly paclitaxel and carboplatin (CTX).

Paraffin-embedded tissue was evaluated for expression of TP, thymidylate synthase and dihydropyrimidine dehydrogenase by immunohistochemistry.

RESULTS: 32 patients from Ohio State University (OSU) were enrolled.

There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.

In normal tissue, there was no difference in expression levels of both TS and TP.

On the other hand, in cancer tissue, TP levels seem to correlate with response whereas TS did not.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961879.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

130 pts were evaluable for PN at time of analyses.

Genotypes of TS and MTHFR could be identified as independent risk factors for grade 3 PNP by multivariate analyses.

Pts carrying a TS promoter genotype known to be associated with low TS expression (2R/2R, 2R/3RC, 3RC/3RC) were at higher risk for developing grade 3 PNP compared to pts without one of these genotypes (OR 3.0 [95%CI 1.27; 7.06], p=0.01).

CONCLUSIONS: Polymorphisms of TS and MTHFR might be associated with grade 3 PNP in AGC pts receiving oxaliplatin based chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963519.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 4083 Background: Thymidylate synthase (TS) over-expression is associated with 5-FU resistance.

Pre-clinical studies demonstrate that vorinostat down-regulates intra-tumor TS in a dose-dependent fashion and augments 5-FU antitumor activity in xenograft models.

METHODS: Vorinostat was escalated in a standard 3 x 3 design in combination with a fixed dose of 5-FU and LV (simplified de Gramont regimen, sFULV2).

Dose-limiting toxicities (DLT), consisting of fatigue and hand-and-foot syndrome (H&F), were seen in 2 of 3 pts at the 2000 mg DL.

An expanded MTD cohort is accruing to investigate 5-FU-vorinostat PK interaction and intra-tumor TS down-regulation. (This work was supported by a grant from CTEP and the ACS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961640.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of genetic polymorphisms on toxicity and survival in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with carboplatin (CBDCA) and pemetrexed disodium regimen.

We investigated the influence of ten single nucleotide polymorphisms (SNPs) of 7 genes (P53 Arg72Pro (G/C); XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); ERCC1 Asn118Asn (C/T); GARFT C/G, GARFT C/T, DHFR C/G, DHFR A/G, TS 5'UTR, TS 3'UTR involved with metabolism of CBDCA and Alimta regimen in pts with advanced NSCLC.

Polymorphisms were detected with TaqMan-probe based assays using the 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA) or PCR followed by RFLP.

Overall response rate was 38.6%, stable disease 38.6% and disease progression 21.1%.

The median progression free survival (PFS) was 7.4 months, the median survival time not reached.

No associations were found between the analyzed polymorphisms and toxicity considered either as the maximum observed grade, or as sum of each toxicity pattern grade, probably due to low number of events observed for toxicity within this data set.

Further studies are warranted to validate this finding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962578.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Due to the cost and potential toxicity of the combination, the endpoint for this phase II study was very ambitious: at least 25% of complete response (medically or surgically achieved), lasting a minimum of 12 months in advanced untreated colorectal cancer patients with clearly unresectable disease.

RESULTS: Of 26 patients (16 with 1 site of disease), 17 completed the first 4 months of treatment according to the protocol, while 9 had to discontinue one biologic drug due to side effects (5 cetuximab, 3 imatinib and 1 bevacizumab).

No evidence of macroscopic disease after the entire treatment plan was obtained in 13/26 patients: 12 surgical and 1 medical CR.

Seven/13 were disease free at 6 months, but only 3 were still disease free at 12 months.

ERCC1, ERCC2/XDP, GSTP1,TS,EGF, COX2, CYCLIN D, FCgR polymorphisms and K-RAS mutations were evaluated on all 26 patients, but no correlations were found with clinical outcome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964491.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In 2005, our group reported low surgical resection rates despite detection of small sized tumors in a prospective surveillance cohort of 1018 HBV carriers (Mok TS et al.

In current study, we aim to identify predictive factors for treatment outcomes in HCC detected from our surveillance program.

After median follow-up of 9.95 years, we confirmed diagnosis of 105 HCC.

Median age = 51 (range: 40-69); M:F = 82:23; Child's A and B cirrhosis = 38:67.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963096.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 6084 Background: The main purpose of the present study was to find predictive biomarkers that can be routinely used for the response to chemotherapy in head and neck squamous cell carcinomas.

METHODS: Sixty-four tumor specimens from patients undergoing radical treatment for squamous cell carcinomas of the oro- and hypopharynx in stage II, III, or IV, were included in the present study.

Using biopsy specimens, we analyzed their gene expression profiles with the following 25 markers, which we thought were likely predictors of the response to anti-cancer agents: TS, DPD, OPRT, TP, COX2, MDR1, MRP1, VEGF, EGFR, HER2, PIK3CA, PTEN, p53, Rb1, Bcl2, BclX, BAX, GSTπ, ERCC1, XPA, E2F1, ENT1, Rev3, β-tubulin, and Survivin.

These mRNA expressions were quantified by real-time reverse transcription polymerase chain reaction (real-time RT-PCR) assay.

Clinical markers, such as T and N factor, gender and age were added, and logistic regression analysis and likelihood ratio test were conducted.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961950.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil.

: 4066 Background: The possible role of uridine diphosphate-glucuronosyltransferase 1A (UGT1A) and Thymidylate Synthase (TS) gene polymorphisms in predicting toxicity and outcomes in irinotecan/ 5-Fluorouracil (5FU)-treated patients is still controversial.

The aim of this work was to determine whether UGT1A1, UGT1A7, and UGT1A9 as well as TS polymorphisms affect toxicities and/or outcomes of Spanish patients with advanced colorectal cancer (mCRC) Methods: A total of 149 patients with mCRC were treated either with weekly irinotecan plus high-dose 5FU (FUIRI) or biweekly irinotecan plus 5FU/Leucovorin (FOLFIRI) as first-line chemotherapy (Aranda E; Ann Oncol.

Chi-square test, Fisher's exact test and logistic regression were used to study the association of genotypes with toxicity and response.

RESULTS: According to TS 5'TRP genotypes, 79.3% of the 2R/2R patients responded to therapy while only 52.5% of 2R/3R or 3R/3R patients do so (HR=3.5; 95% CI=1.3- 9.1; p=0.009).

TS genotypes were not associated with toxicity.

TS 5'TRP genotypes are predictive of response to irinotecan/5FU first-line chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961607.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, GST, TS, and UGT1A1predicted overall survival in gastric cancer patients receiving FOLFOX and/or FOLFIRI chemotherapy.

The PCR- restriction fragment length polymorphism (RFLP) method was applied to detect the known variant sites of ERCC1, GST, TS, and UGT1A1.

Only the GSTM1 positive genotype showed a significantly better time to progression (P=0.023).

But significant genotype variation of TS, GST and ERCC1,which assumed to affect to activity of oxaliplatin was not observed to RR, toxicity, and overall survival.

Low expression type (2R/2R, 2R/3C, and 3C/3C) of TS was associated with high incidence of grade ≥3 neutropenia.

CONCLUSIONS: In this study, GSTM1 positive genotype showed a significantly better time to progression in the advanced gastric cancer treated with FOLFOX.

Low expression type (2R/2R, 2R/3C, and 3C/3C) of TS was associated with high incidence of grade ≥3 neutropenia in the advanced gastric cancer treated with FOLFIRI.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962361.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tumor tissue and blood sample was analyzed for the translational research.

Twenty two pts (51.2%) had stable disease.

Overall disease control rate was 83.7%.

EGFR, pEGFR, TS, TP, DPD was overexpressed in 77.4%, 17.1%, 82.4%, 53.6% and 61.3% of tumor tissues respectively.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964140.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 6052 Background: Unresectable/metastatic squamous cell cancer of the head and neck (SCCHN) has a poor prognosis despite standard therapy with cisplatin.

One prior therapy for recurrent disease was allowed.

Median age was 64 years (range, 49-82); 10 males; 13 smokers (including 4 current smokers).

15 patients previously received definitive therapy with surgery and/or chemo-RT, and 9 had prior systemic therapy for recurrent/metastatic disease.

Reasons for treatment discontinuation included progressive disease in 15 patients and decreased PS in 1.

Further study of this regimen should be considered in patients enriched for TS and RRM1 status.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961917.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

ERCC1, TS, kRas mutations but the comparatively small number of known cellular analytes has limited their broad application.

METHODS: To address the complexity and redundancy of cell-death signaling pathways, we applied Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) (Nagourney, R.

Accrual continues with current TTP ranges from 1.2-17.3 months and OS from 2.5 to 30 months.

By examining drug-induced cell death events in native-state microspheroids, this platform has the unique capacity to capture stromal, vascular and inflammatory cell interactions with tumor cells, now known to be crucial for clinical response prediction.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960832.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The mechanism of action of platinum compounds such as oxaliplatin is to bind to a DNA molecule in the form of a platinum-DNA-adduct.

Thymidylate synthase (TS) and dehydropyrimidine dehydrogenase (DPD) are key enzymes of 5-FU metabolism and are well known to be associated with a response to 5-FU-based therapy.

METHODS: Twenty-one colorectal cancer patients (male:female = 7:14; median age, 65) treated with a combination of oxaliplatin and S-1 as a first-line therapy were analyzed for ERCC1 codon 118 polymorphism and the mRNA expression levels of TS, ERCC1, and DPD.

The mRNA expression levels were measured using real-time RT-PCR, and the polymorphism was analyzed using the allelic discrimination method together with real-time PCR.

Patients with both high TS and ERCC1 mRNA levels showed a significantly lower response rate than the others (25% vs. 67%, p=0.02).

CONCLUSIONS: The mRNA expression levels of TS and ERCC1 appear to be useful markers for the treatment of S-1 and oxaliplatin.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964567.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 6085 Background: We evaluated the prognostic significance of thymidylate synthase (TS), and Excision Repair Cross-Complementation Group 1 protein (ERCC1) in patients (pts) with nasopharyngeal cancer (NPC) treated with concurrent chemoradiotherapy (CCRT).

METHODS: Pretreatment tumor biopsy specimens from 41 pts with locally advanced NPC were analyzed for TS and ERCC1 expression by immunohistochemistry.

High expression of TS and ERCC1 was observed in 21 (51%) and 25 (60%) pts, respectively.

In univariate analysis, high expression of ERCC1 was associated with poor OS (5-year: 73% versus 35%; p = 0.005), while high expression of TS was not correlated with pts outcome (p = 0.867).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961951.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Thymidilate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and dihydrofolate reductase (DHFR) as predictive markers of capecitabine efficacy in breast cancer patients.

The expression and/or gene copy number of TS, TP, DPD and DHFR was assessed and correlated with time-to progression (TTP) and progression-free survival (PFS).

METHODS: Adult female patients with pathologically confirmed breast cancer and locally advanced or metastatic disease were treated with C 1000 mg/m² BID days 1-14 of a 21-day cycle.

Total RNA was isolated from 32 FFPE tissue samples containing at least 70% tumor cells and RNA levels for TS, TP, DPD and DHFR were quantified using real time RT-PCR and Affymetrix GeneChip microarrays.

Custom made TS and TP FISH probes (Dako, Glostrup, Denmark) were used to evaluate gene copy number and gene to reference ratios in at least 60 morphologically intact non-overlapping nuclei.

RESULTS: Higher TS gene copy number was significantly associated with a decrease in PFS (HR 1.46, 95% CI 1.08 to 1.96, p=0.014) and TTP (HR 1.49, 95% CI 1.05 to 2.13, p=0.028).

However, the association between TS RNA levels (expressed as Ct values) and PFS (HR 0.82, 95% CI 0.61 to 1.11, p=0.198) or TTP (HR 0.74, 95% CI 0.49 to 1.14, p=0.172) failed to reach statistical significance.

RNA levels, determined by Affymetrix, were significantly correlated with RT-PCR for TS (r= -0.5073, p=0.0004) and DHFR (r=-0.50994, p=0.003).

CONCLUSIONS: These data indicate that TS gene copy number, assessed by FISH with proper standardization, might be a useful and easily accessible marker for C sensitivity in human breast cancer and warrants further investigation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964007.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The median time from diagnosis of metastatic breast cancer to the initiation of IF therapy was 34 months (range: 12-97 months).

The used regimens were: FOLFIRI (18 patients), TS-1/ irinotecan (6), capecitabine/irinotecan (1).

Stable disease was shown in 29.2% and 70.8% was PD, that is disease control rate was 29.2% (95% CI:10-45%).

The median duration of disease control was 3.9 months (95% CI 3.7-4.2, range 2.4-11).

And the major Gr 3/4 non-hematologc toxicity was: diarrhea (4%), hand-foot syndrome (0%), fatigue (0%).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964261.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

TS expression is regulated by a polymorphism in the TSER and has been shown that pts with S/S variant have high response rate and increased toxicity in colon cancer pts.

Grade 3 hand foot syndrome, diarrhea and vomiting were dose limiting toxicities.

The pt who received 3 cycles came off study due to progressive disease and the other 3 pts came of the study due to toxicities.

TSER polymorphism was correlated to OS and only S/S variant was significant with a trend towards improved OS by log rank test and Kaplan Meier plot.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963738.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Gene expression was quantitated by RT-PCR from 30 μm manually microdissected fixed paraffin-embedded primary colon cancer tissue.

Recurrence-free interval (RFI), disease-free survival (DFS), and overall survival (OS) were analyzed using Cox regression.

Multivariate analysis, in the context of stage, grade, nodes examined, and MSI status, yielded 18 genes (7 prognostic genes, 6 predictive genes, 5 reference genes) and separate prognostic recurrence score (RS) and predictive treatment score (TS) algorithms.

However, TS was not validated as a predictor of 5FU/LV benefit (interaction p=0.19).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961827.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Polymorphisms of GSTP1, GSTT1, GSTM1, MTHFR, TS, ERCC1, and ERCC2 in metastatic colorectal cancer treated by first-line mFOLFOX6 chemotherapy.

Polymorphisms of 5 genes involved in drug metabolism (glutathione S-transferase (GST) P1 (IIe 105 Val), GSTT1 deletion, and GSTM1 deletion, methylenetetrahydrofolate reductase (MTHFR) (Ala 677 Val), and a 6-base pair (bp) deletion in the 3'-untranslated region (UTR) of thymidylate synthase (TS)), and polymorphisms of two DNA repair genes (excision repair cross complementing group 1 (ERCC1): Asp 118 Asn and ERCC2: Lys 751 Gln) were assessed in these patients by PCR-RFLP or the invader technique.

RESULTS: The distribution of the genotypes of GSTP1, GSTT1, TS, ERCC1, and ERCC2 in the present Japanese patients (but not that of GSTM1 or MTHFR), differed significantly from the distribution of these genotypes in a Caucasian population.

However, patients who had both alleles containing the 6-bp nucleotide fragment in the 3'UTR of TS showed significantly shorter overall survival than those who had at least one allele without the 6-bp nucleotide fragment (p=0.03).

CONCLUSIONS: These results suggest that 3'UTR polymorphism of TS may be an important predictor of overall survival for Japanese patients with metastatic colorectal cancer receiving first-line 5-FU/oxaliplatin therapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964222.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e16163 Background: Thymidylate synthase ( TS ) is an important enzyme in de novo DNA synthesis pathway.

5-Fluorouracil ( 5-FU ), an anticancer chemotherapeutic agent used clinically against a variety of cancers including prostate cancer, inhibits DNA synthesis by binding TS.

In the present study, we examined TS expression in prostate cancer and investigated its prognostic significance.

METHODS: Fifty-two prostate cancer tissue specimens were obtained from patients who underwent radical prostatectomy for prostate cancer without neoadjuvant hormonal therapy.

Forty-eight prostate cancer tissue specimens were also obtained from patients who underwent radical prostatectomy for prostate cancer with neoadjuvant hormonal therapy.

We examined prostate cancer tissue and normal prostate tissue for TS expression by immunohistochemistry.

RESULTS: TS was expressed at higher levels in prostate cancer without neoadjuvant hormonal therapy, compared with normal prostate.TS expression in stage T3 prostate cancer was higher than that in stage T2 prostate cancer.

In addition, the level of TS expression in Gleason score 7 or greater prostate cancer was higher than that in Gleason score less than 7 prostate cancer.

Patients with prostate cancer with negative TS expression without neoadjuvant hormonal therapy had a longer postoperative recurrence-free rate than those with positive expression in the 5 year follow-up.

In addition, patients with Gleason score less than 7 prostate cancer with negative TS expression had a much longer postoperative recurrence-free rate than those with positive expression in the 5-year follow-up.

TS expression was significantly decreased in prostate cancer patients who received neoadjuvant hormonal therapy, especially stage T2 prostate cancer patients.

CONCLUSIONS: The current study has demonstrated for the first time that TS expression may be a prognostic parameterr for prostate cancer patients undergoing radical prostatectomy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963439.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 7508 Background: Pemetrexed has shown activity in malignant pleural mesothelioma (MPM) but scanty data are available on the expression of thymidylate synthase (TS), its most important molecular target.

METHODS: From a database of 75 non-surgical, chemotherapy-naive MPM patients from our Institution in the period 2004-2008, 50 (male/female: 37/13, median age: 65 years) met the selection criteria i.e. epithelial type, availability of thoracoscopic tissue and outcome data.

Retrospectively TS protein expression levels were evaluated by immunohistochemistry and quantified with H-score method.

In addition, mRNA extraction was performed in 23 micro-dissected tissues and TS relative levels quantified by RT-PCR.

Survival probability was assessed by Kaplan-Meier method and results compared by log-rank test.

RESULTS: Thirty-two patients had progressive disease and 24 had died at the time of the analysis.

Median time to progression (TTP) and median survival time (MST) were 11.6 and 20.9 months, respectively.

Median TS H-score value was 90 (5-240).

Patients with high TS H-score (4th quartile) had a significantly shorter MST (13.3 vs 21.1 months, p<0.01) and showed a trend for shorter TTP (8.3 vs 11.9 months, p=0.07).

Median TS mRNA level was 1.88 (1-3.7 unit-less ratio) and a significant correlation between mRNA and protein expression (RS=0.67, p<0.0001) was found.

Patients with high TS mRNA levels (4th quartile) had significantly shorter TTP (8.7 vs 14.7 months, p=0.019) and MST (11.7 vs 24.7, p=0.018).

Multivariate analysis for survival indicated that TS protein levels were an independent prognostic factor (HR=2.17; CI 1.04-4.54; p=0.038).

CONCLUSIONS: TS (protein and mRNA) levels predict outcome of epithelial MPM patients treated with pemetrexed-based chemotherapy.

TS quantification, if confirmed in larger prospective studies, could be used to select those patients more likely to respond to chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963478.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Gene expression levels of thymidylate synthase (TS), thymidylate phosphorylase (TP), epidermal growth factor receptor (EGFR) and excision repair cross complementing (ERCC-1) have been shown to be associated with outcomes in lung, gastric and colon cancer.

We evaluated TS, ERCC-1, EGFR and TP gene expression levels in patients with UGI cancers.

The primary objective was to determine a correlation between TS, TP, ERCC1 and EGFR and correlate with clinical outcome.

Characteristics of these 80 pts: (16 females, 64 males ); median age 61 years (range 34-85); tumor types evaluated - 32 (40%) esophageal, 24(30%) gastric, 24(30%) GE junction; stages- 53 % IV, 21% III, 12% II, 2% I were evaluated for intratumoral gene expression of TS, TP, ERCC-1, & EGFR by real time quantitative PCR using Taqman technology from microdisected paraffin-embedded tumor sections.

RESULTS: High TS expression was associated with shorter OS (12.8 months vs. 23.7 months p=0.036).

A significant correlation was found between TP & ERCC-1 (p=0.0078, r=0.37); TP & TS (p=0.0128, r=0.35); TP & EGFR (p=0.0065, r=0.39); TS & ERCC-1 (p=0.0004, r=0.39); ERCC-1 & EGFR (p=0.025, r=0.30).

No statistically significant relationship was found between TS & EGFR (p=0.06,r=0.25).

CONCLUSIONS: TS mRNA levels were shown to be associated with OS in UGI tumors, consistent with data reported in colon cancer.

TS gene expression was significantly associated with expression levels of ERCC-1.

These data show for the first time that molecular pathways of cytotoxic agents are linked to the EGFR pathway suggesting that sensitivity to fluoropyrimidines, oxaliplatin, and EGFR inhibitors may be associated.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963224.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MRI appearance of Sturge-Weber syndrome in tuberous sclerosis complex: is the neural crest the culprit?

Several neurocutaneous syndromes have been reported in association with tuberous sclerosis complex.

The coexistence of intracranial features of Sturge-Weber syndrome in patients with a confirmed diagnosis of tuberous sclerosis complex has been recently described.

The coexistence of signs of both diseases in the same patient could be explained by abnormal neural crest development, and by mutually enhanced common altered pathways.

Mutation characterization of tuberous sclerosis complex and a better definition of the clinical and neuroimaging phenotypes could offer a crucial contribution to the etiopathogenetic mechanisms of these disorders.

[MeSH-major] Neural Crest / embryology. Sturge-Weber Syndrome / complications. Sturge-Weber Syndrome / pathology. Tuberous Sclerosis / complications

[MeSH-minor] Brain / pathology. Humans. Magnetic Resonance Imaging. Mutation, Missense. Neovascularization, Pathologic. Tumor Suppressor Proteins / genetics

Genetic Alliance. consumer health - CREST Syndrome.

Genetic Alliance. consumer health - Sturge-Weber syndrome.

Genetic Alliance. consumer health - Tuberous sclerosis.

Genetic Alliance. consumer health - Weber syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Child Neurol. 2009 Mar;24(3):333-7 [19258292.001]

(PMID = 19258284.001).

[ISSN] 1708-8283

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Comment; Editorial

[Publication-country] United States

[Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neuroimaging in tuberous sclerosis complex.

PURPOSE OF REVIEW: In this review we discuss recent advances in the neuroimaging of patients with tuberous sclerosis complex (TSC), highlighting its application in improving clinical management, particularly in the case of intractable epilepsy.

RECENT FINDINGS: Progress in structural and functional imaging has led to further characterization of the brain lesions in TSC.

New magnetic resonance imaging techniques that can delineate the extent of structural brain abnormalities in TSC have been developed.

Diffusion tensor imaging unveils the microstructural abnormalities of the brain lesions and of the morphologically normal appearing white matter in TSC.

Positron emission tomography scanning with 2-deoxy-2-[18F]fluoro-D-glucose can assess the full extent of functional brain abnormalities in TSC.

The use of alpha [11C] methyl-L-tryptophan positron emission tomography scanning has proven to be a useful tool in the identification of epileptogenic tubers and has improved the outcome of surgery for epilepsy in TSC.

SUMMARY: Major advances of neuroimaging in TSC have shown evidence of widespread structural and functional brain abnormalities.

In TSC patients with intractable epilepsy, new neuroimaging modalities can now provide an accurate assessment of the epileptogenic zone, thereby permitting improved identification of patients who can have good seizure outcome following surgery for epilepsy.

[MeSH-major] Brain / pathology. Magnetic Resonance Imaging / methods. Tuberous Sclerosis / diagnosis

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - MRI Scans.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17351483.001).

[ISSN] 1350-7540

[Journal-full-title] Current opinion in neurology

[ISO-abbreviation] Curr. Opin. Neurol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 65

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Study of the relationship between tuberous sclerosis complex and autistic disorder.

There has been increasing awareness that there are behavioral phenotypes in tuberous sclerosis complex with neuropsychiatric symptom complex such as autistic disorder and attention-deficit hyperactivity disorder (ADHD).

However, the neurobiologic basis of autistic disorder in tuberous sclerosis complex is still unknown.

We studied two cohorts of children followed up since 1986 until 2003, one cohort with tuberous sclerosis complex and another cohort with autistic disorder, to determine the incidence of autistic disorder in tuberous sclerosis complex and the incidence of tuberous sclerosis complex in autistic disorder respectively.

We established a Tuberous Sclerosis Complex Registry in 1985 at the University of Hong Kong.

Three had a positive family history of tuberous sclerosis complex.

Thus, the total number of tuberous sclerosis complex cases was 47.

We adopted the diagnostic criteria of tuberous sclerosis complex for case ascertainment.

The period prevalence rate of tuberous sclerosis complex for children and adolescents aged < 20 years is 3.5 per 10,000 (on Hong Kong island, excluding the eastern region with 125,100 aged < 20 years in 2003).

Of 44 cases with tuberous sclerosis complex, 7 had autistic disorder.

Thus, the incidence of autistic disorder in tuberous sclerosis complex is 16%.

During the 17-year period (1986-2003), we collected a database of 753 children (668 boys and 84 girls; male to female ratio 8:1) with autistic disorder and pervasive developmental disorders.

For all children with autistic disorder or pervasive developmental disorders, we routinely examined for any features of tuberous sclerosis complex by looking for neurocutaneous markers such as depigmented spots, which appear in 50% of children with tuberous sclerosis complex by the age of 2 years.

For those with infantile spasm or epilepsy, the clinical features of tuberous sclerosis complex were monitored regularly during follow-up.

Of these, seven had tuberous sclerosis complex.

Thus, the incidence of tuberous sclerosis complex in autistic disorder is 0.9%.

Future studies should be directed toward looking at the various behavioral phenotypes in tuberous sclerosis complex and defining these with standardized criteria to look for any real association with the underlying genetic mutation of TSC1 or TSC2 gene or even the site of tubers in the brain.

[MeSH-major] Autistic Disorder / epidemiology. Tuberous Sclerosis / epidemiology

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16901420.001).

[ISSN] 0883-0738

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intrafamilial phenotypic variability in tuberous sclerosis complex.

Clinical manifestations were retrospectively assessed in 5 families with tuberous sclerosis complex, including 1 pair of monozygotic twins.

Interfamilial variation in tuber count was significantly larger than intrafamilial variation.

Severity of epilepsy and cognitive profiles varied both between and within families, particularly between the monozygotic twins, and IQ was inversely related to tuber count.

Although the monozygotic twins displayed similar physical manifestations of tuberous sclerosis complex (renal and cardiac hamartomas), they differed markedly in neurocognitive profiles.

Phenotypic variation within these families may be explained largely as a function of the randomness of second-hit events that cause hamartomas in tuberous sclerosis complex or by as-yet-unidentified genetic modifiers.

Familial variation in tuberous sclerosis complex phenotype has important implications for genetic counseling.

[MeSH-major] Family. Glioma / diagnosis. Phenotype. Tuberous Sclerosis / genetics

[MeSH-minor] Adolescent. Adult. Aged, 80 and over. Child. Child, Preschool. Cognition. Diseases in Twins / diagnosis. Diseases in Twins / genetics. Epilepsy / diagnosis. Epilepsy / genetics. Female. Genetic Variation. Humans. Infant. Intelligence / genetics. Magnetic Resonance Imaging. Male. Mental Disorders / diagnosis. Mental Disorders / genetics. Middle Aged. Neuropsychological Tests. Observer Variation. Pedigree. Penetrance. Retrospective Studies. Severity of Illness Index. Twins, Monozygotic / genetics

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Family Issues.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18174550.001).

[ISSN] 0883-0738

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Canada

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prenatal molecular diagnosis of tuberous sclerosis complex.

OBJECTIVE: The objective of the study was to report experience with prenatal molecular diagnosis of tuberous sclerosis complex (TSC).

STUDY DESIGN: Sequential deoxyribonucleic acid (DNA) studies were performed on amniotic fluid cells and chorionic villi from 50 pregnant women at risk for having a child with TSC.

Mutations were determined by gene sequencing and deletion/duplication analysis of the 2 TSC genes.

In 4 of 18 cases, a mutation was detected in the fetus for the first time despite a parent known to have TSC.

CONCLUSION: The value and utility of prenatal diagnosis of TSC by DNA analysis was demonstrated by the results in this series of 50 pregnancies in women at risk of having affected offspring.

A family history of TSC or detection of fetal cardiac rhabdomyoma should prompt genetic evaluation and counseling of parents and the option of prenatal diagnosis.

[MeSH-major] Genetic Testing. Prenatal Diagnosis / methods. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / genetics

[MeSH-minor] Family Health. Female. Genetic Counseling. Heart Neoplasms / diagnosis. Heart Neoplasms / epidemiology. Heart Neoplasms / genetics. Humans. Polymorphism, Genetic. Pregnancy. Rhabdomyoma / diagnosis. Rhabdomyoma / epidemiology. Rhabdomyoma / genetics. Risk Factors

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Genetic Testing.

MedlinePlus Health Information. consumer health - Prenatal Testing.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19254590.001).

[ISSN] 1097-6868

[Journal-full-title] American journal of obstetrics and gynecology

[ISO-abbreviation] Am. J. Obstet. Gynecol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cognitive prognosis of patients with tuberous sclerosis complex.

To assess cognitive outcome in patients with tuberous sclerosis complex (TSC) and identify predictive risk factors, we reviewed records of 107 patients who underwent comprehensive neuropsychiatric evaluation.

Fifty-seven percent of patients with TSC had normal-range IQ/developmental quotient (DQ).

In TSC, IQ/DQ is bimodally distributed, and more than half of individuals are in the normal range.

[MeSH-major] Cognition Disorders / diagnosis. Tuberous Sclerosis / diagnosis

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17200495.001).

[ISSN] 1526-632X

[Journal-full-title] Neurology

[ISO-abbreviation] Neurology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lymphangioleiomyomatosis and tuberous sclerosis complex.

Lymphangioleiomyomatosis (LAM) is a rare multisystemic disease of women of child-bearing age and affects mainly the lungs, promoting cystic destruction of lung parenchyma or leading to abdominal tumor formation (e.g., angiomyolipomas, lymphangioleiomyomas).

LAM can arise sporadically or in association with tuberous sclerosis complex (TSC), an autosomal inherited syndrome characterized by hamartoma-like tumor growth and pathologic features that are distinct from manifestations of pulmonary LAM.

A substantial body of evidence has now been gathered suggesting that the two diseases share a common genetic origin.

TSC is caused by mutations in two genes, TSC1 on chromosome 9q34 and TSC2 on 16p13.

Sporadic LAM is correlated with a mutation in the TSC2 gene and tuberin appears to play a central role in the pathogenesis of the disease.

A TSC2 loss or mutation leads to disruption of the tuberin-hamartin heteromer and dysregulation of S6K1 activation leading to aberrant cell proliferation seen in LAM disease.

The extremely diverse clinical and radiologic features of the disease and the complex therapeutic approach are reviewed in detail.

As long as newer therapeutic agents do not change this picture, lung transplantation remains the last hope for patients with respiratory failure at the advanced stage of the disease.

[MeSH-major] Lung. Lymphangioleiomyomatosis. Tuberous Sclerosis

[MeSH-minor] Disease Progression. Genetic Predisposition to Disease. Humans. Matrix Metalloproteinases / metabolism. Risk Factors. Tissue Inhibitor of Metalloproteinases / metabolism. Treatment Outcome

Genetic Alliance. consumer health - Lymphangioleiomyomatosis.

Genetic Alliance. consumer health - Tuberous sclerosis.

Genetics Home Reference. consumer health - TSC1 gene.

Genetics Home Reference. consumer health - TSC2 gene.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 1996 Oct 24;335(17):1275-80 [8857007.001]

[Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):1002-9 [10712355.001]

[Cites] Am Rev Respir Dis. 1991 Jan;143(1):174-6 [1824744.001]

[Cites] N Engl J Med. 2006 Jun 15;354(24):2621-2 [16775248.001]

[Cites] Am J Respir Cell Mol Biol. 2003 Apr;28(4):504-11 [12654640.001]

[Cites] Oncogene. 2005 Nov 14;24(50):7475-81 [16288294.001]

[Cites] Hum Pathol. 2003 Jan;34(1):95-8 [12605373.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700 [12922981.001]

[Cites] Am J Respir Crit Care Med. 2003 Dec 15;168(12 ):1427-31 [12958050.001]

[Cites] Am J Respir Crit Care Med. 2005 Jan 1;171(1):61-7 [15466255.001]

[Cites] Chest. 2004 Dec;126(6):1867-74 [15596686.001]

[Cites] Thorax. 2002 Dec;57(12):1085-6 [12454306.001]

[Cites] Radiology. 2002 Oct;225(1):78-82 [12354988.001]

[Cites] Medicine (Baltimore). 1999 Sep;78(5):321-37 [10499073.001]

[Cites] Eur Respir J. 2004 Dec;24(6):910-7 [15572531.001]

[Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90 [10823953.001]

[Cites] Thorax. 2005 Oct;60(10):875-9 [16055626.001]

[Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]

[Cites] Proc Am Thorac Soc. 2008 Jan 1;5(1):119-26 [18094094.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L690-3 [15003933.001]

[Cites] Nat Cell Biol. 2002 Sep;4(9):E214-6 [12205484.001]

[Cites] Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1537-40 [11704609.001]

[Cites] Hum Pathol. 2000 Oct;31(10):1242-8 [11070117.001]

[Cites] Am J Transplant. 2006 Sep;6(9):1991-9 [16930395.001]

[Cites] Hum Pathol. 1997 Dec;28(12):1420-3 [9416700.001]

[Cites] Am J Respir Cell Mol Biol. 2003 May;28(5):546-50 [12707009.001]

[Cites] J Biol Chem. 1995 Jul 7;270(27):16409-14 [7608212.001]

[Cites] Chest. 2002 Mar;121(3 Suppl):61S [11893688.001]

[Cites] Am J Respir Crit Care Med. 2001 Sep 15;164(6):1072-6 [11587999.001]

[Cites] Chest. 2006 May;129(5):1274-81 [16685019.001]

[Cites] J Cell Biochem. 2008 Feb 1;103(2):369-82 [17541983.001]

[Cites] Am J Surg Pathol. 1993 Nov;17(11):1092-102 [8214254.001]

[Cites] Am J Respir Crit Care Med. 2006 Jan 1;173(1):105-11 [16210669.001]

[Cites] Chest. 2000 Jan;117(1):25-30 [10631194.001]

[Cites] Thorax. 1984 Nov;39(11):818-22 [6505988.001]

[Cites] J Med Genet. 2000 Jan;37(1):55-7 [10633137.001]

[Cites] Thorax. 1994 Sep;49(9):910-4 [7940433.001]

[Cites] Chest. 1999 Jan;115(1):276-9 [9925099.001]

[Cites] Ann Intern Med. 2007 May 1;146(9):687-8 [17470843.001]

[Cites] Chest. 2003 Feb;123(2):623-7 [12576391.001]

[Cites] Chest. 2004 Jan;125(1):135-42 [14718432.001]

[Cites] Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S31-9 [16457015.001]

[Cites] Cancer Control. 2006 Oct;13(4):276-85 [17075565.001]

[Cites] Clin Exp Obstet Gynecol. 2005;32(3):199-200 [16433165.001]

[Cites] J Heart Lung Transplant. 2005 Sep;24(9):1247-53 [16143241.001]

[Cites] Am J Respir Crit Care Med. 1995 Jun;151(6):2033-6 [7767554.001]

[Cites] Thorax. 1999 Mar;54(3):254-64 [10325903.001]

[Cites] Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S49-66 [16457017.001]

[Cites] Am J Respir Crit Care Med. 2003 Apr 1;167(7):976-82 [12411287.001]

[Cites] Am J Physiol Cell Physiol. 2003 Aug;285(2):C409-18 [12700139.001]

[Cites] Am J Clin Pathol. 1991 Oct;96(4):529-35 [1716416.001]

[Cites] Rev Mal Respir. 1996 Jul;13(3):300-4 [8765924.001]

[Cites] Thorax. 2004 Sep;59(9):800-3 [15333859.001]

[Cites] Chest. 1989 Dec;96(6):1352-5 [2582843.001]

[Cites] Contraception. 2000 Jun;61(6):385-90 [10958882.001]

[Cites] Mayo Clin Proc. 1995 Jul;70(7):641-8 [7791386.001]

[Cites] Eur Respir J. 2006 May;27(5):1056-65 [16707400.001]

[Cites] Am J Pathol. 2006 May;168(5):1697-709 [16651635.001]

[Cites] Am J Hum Genet. 1998 Apr;62(4):810-5 [9529362.001]

[Cites] Chest. 2008 Feb;133(2):507-16 [18252917.001]

[Cites] Br J Dis Chest. 1985 Oct;79(4):400-6 [2932139.001]

[Cites] S D J Med. 2005 Apr;58(4):139-43 [15861601.001]

[Cites] Am J Respir Cell Mol Biol. 2006 Jul;35(1):40-7 [16474096.001]

[Cites] Respir Med. 2002 Jan;96(1):7-13 [11863212.001]

[Cites] Am J Respir Crit Care Med. 1999 Aug;160(2):628-33 [10430739.001]

[Cites] Hum Pathol. 1997 Sep;28(9):1071-8 [9308732.001]

[Cites] Ther Drug Monit. 2006 Oct;28(5):577-84 [17038868.001]

[Cites] Chest. 2008 Feb;133(2):448-54 [18071009.001]

[Cites] Respir Med. 2004 Jun;98(6):536-41 [15191039.001]

[Cites] Semin Respir Crit Care Med. 2002 Apr;23(2):85-92 [16088601.001]

[Cites] J Biol Chem. 1999 Dec 10;274(50):35647-52 [10585443.001]

[Cites] Radiology. 2000 Feb;214(2):441-6 [10671592.001]

[Cites] Chest. 1998 Dec;114(6):1689-703 [9872207.001]

[Cites] Thorax. 2000 Dec;55(12):1052-7 [11083892.001]

[Cites] Am J Surg Pathol. 1999 Sep;23(9):1011-20 [10478660.001]

[Cites] J Biol Chem. 2002 Aug 23;277(34):30958-67 [12045200.001]

[Cites] J Womens Health (Larchmt). 2003 Jan-Feb;12(1):81-5 [12639372.001]

[Cites] Cell. 1995 Jun 30;81(7):1159-70 [7600583.001]

[Cites] Am J Respir Crit Care Med. 2001 Aug 15;164(4):669-71 [11520735.001]

[Cites] Arch Pathol Lab Med. 2000 Feb;124(2):267-75 [10656737.001]

[Cites] Clin Chest Med. 2006 Jun;27(2):355-68 [16716823.001]

[Cites] J Radiol. 2006 Dec;87(12 Pt 1):1859-67 [17213770.001]

[Cites] Am J Respir Cell Mol Biol. 2006 May;34(5):561-72 [16424383.001]

[Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]

(PMID = 18408969.001).

[ISSN] 0341-2040

[Journal-full-title] Lung

[ISO-abbreviation] Lung

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases

[Number-of-references] 85

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Psychological profile of adults with tuberous sclerosis complex.

The Symptom Checklist-90-Revised, a standardized self-report measure of psychological symptoms, was administered to 42 adults with tuberous sclerosis complex (TSC).

Approximately 45% reported high overall psychological distress, most commonly involving interpersonal sensitivity, psychoticism, depression, and obsessive-compulsive symptoms.

Symptoms were related to number of organ systems affected by TSC and, in some cases, to seizure history, but not to genotype, IQ, education, severity of epilepsy, or use of anticonvulsant or psychiatric medication.

[MeSH-major] Mental Disorders / psychology. Psychological Tests / statistics & numerical data. Tuberous Sclerosis / psychology

[MeSH-minor] Adult. Analysis of Variance. Female. Humans. Intelligence. Intelligence Tests / statistics & numerical data. Male. Middle Aged. Retrospective Studies

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Mental Disorders.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17392032.001).

[ISSN] 1525-5050

[Journal-full-title] Epilepsy & behavior : E&B

[ISO-abbreviation] Epilepsy Behav

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intractable epilepsy in hemimegalencephaly and tuberous sclerosis complex.

Hemimegalencephaly is a rare brain malformation consisting of the enlargement of 1 hemisphere, often associated with abnormal cortical gyration, thick cortex, large neurons, and increased astrocytes.

Hemiparesis, intractable epilepsy, and developmental delay are the typical clinical manifestations.

Tuberous Sclerosis Complex is an autosomal dominant disorder affecting about 1 in 6000 live births; the number of spontaneous mutations is remarkable.

These lesions most frequently involve the brain, skin, kidneys, eyes, and heart.

The rare association of hemimegalencephaly and tuberous sclerosis complex has been reported in a few cases.

The authors report the case of a 4-year-old boy with left hemimegalencephaly, tuberous sclerosis complex genetically confirmed, and intractable epilepsy originating from the nonhemimegalencephalic hemisphere.

[MeSH-major] Epilepsy / etiology. Functional Laterality / physiology. Nervous System Malformations / complications. Tuberous Sclerosis / complications

[MeSH-minor] Child, Preschool. Disease Progression. Electroencephalography / methods. Humans. Magnetic Resonance Imaging. Male

Genetic Alliance. consumer health - Epilepsy.

Genetic Alliance. consumer health - Hemimegalencephaly.

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Brain Malformations.

MedlinePlus Health Information. consumer health - Epilepsy.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17608312.001).

[ISSN] 0883-0738

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bilateral temporal arachnoid cysts associated with tuberous sclerosis complex.

The association between tuberous sclerosis complex and intracranial abnormalities such as hemimegalencephaly, schizencephaly, intracranial arterial aneurysms, and corpus callosum agenesis/dysplasia has been reported in the recent literature.

However, the association between tuberous sclerosis complex and bilateral temporal arachnoid cysts has not been reported.

The neuro-radiological findings are consistent with tuberous sclerosis complex associated with bitemporal arachnoid cysts.

To the authors' knowledge, this is the first reported case of tuberous sclerosis complex associated with bilateral arachnoid cysts of the temporal region.

[MeSH-major] Arachnoid Cysts / complications. Tuberous Sclerosis / complications

Genetic Alliance. consumer health - Arachnoid Cysts.

Genetic Alliance. consumer health - Tuberous sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17641270.001).

[ISSN] 0883-0738

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Canada

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neuroimaging correlation with neurological severity in tuberous sclerosis complex.

OBJECTIVE: To delineate the relationship between neurological severity and neuroimage of lesion load including specific topography of supratentorial cortical tubers and white matter lesions in tuberous sclerosis complex (TSC).

METHODS: Twenty-five TSC patients more than 2 years of age who underwent conventional and fluid-attenuated inversion recovery sequence (FLAIR) magnetic resonance imaging (MRI) were retrospectively studied.

A neuroimaging scoring system was designed to evaluate the load of the cerebrum lesions with respect to location and size of cortical tubers and white matter lesions based on FLAIR MRI.

CONCLUSIONS: The brain lesion load was positively correlated with neurological prognosis in TSC patients.

Patients with larger lesion load in the left temporal lobe may be correlated with increased neurological severity in right-handed patients with TSC.

[MeSH-major] Brain / pathology. Nervous System / pathology. Supratentorial Neoplasms / pathology. Tuberous Sclerosis / pathology

Genetic Alliance. consumer health - Tuberous sclerosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17869556.001).

[ISSN] 1090-3798

[Journal-full-title] European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

[ISO-abbreviation] Eur. J. Paediatr. Neurol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Renal complication in tuberous sclerosis complex].

Authors present the review of current literature on the subject of nephrological complications in tuberous sclerosis complex (TSC) on the basis of two ease reports of children with familial TSC.

In 18-years-old girl the features of polycystic kidney disease with end-stage renal failure, epilepsy, mental retardation, calcifications of structures in central nervous system and skin abnormalities coexist.

In the girl during the one month of observation asymptomatic acute bleeding to a cyst and under the renal capsule occurred.

[MeSH-major] Hemorrhage / etiology. Hemorrhage / radiography. Polycystic Kidney Diseases / radiography. Tuberous Sclerosis / complications

[MeSH-minor] Adolescent. Brain / radiography. Child. Female. Humans. Kidney / radiography. Kidney Diseases / etiology. Kidney Diseases / surgery. Male. Tomography, X-Ray Computed

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Bleeding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18350728.001).

[ISSN] 0043-5147

[Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)

[ISO-abbreviation] Wiad. Lek.

[Language] pol

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Poland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Magnetic source imaging localizes epileptogenic zone in children with tuberous sclerosis complex.

The authors assessed whether magnetoencephalography/magnetic source imaging (MEG/MSI) identified epileptogenic zones in patients with tuberous sclerosis complex (TSC).

In six TSC children with focal seizures, ictal video-EEG predicted the region of resection with 56% sensitivity, 80% specificity, and 77% accuracy (p = 0.02), whereas interictal MEG/MSI fared better (100%, 94%, and 95%, respectively; p < 0.0001).

Interictal MEG/MSI seems to identify epileptogenic zones more accurately in children with TSC and focal intractable epilepsy.

[MeSH-major] Epilepsy / diagnosis. Epilepsy / pathology. Tuberous Sclerosis / diagnosis. Tuberous Sclerosis / pathology

[MeSH-minor] Child. Child, Preschool. Electroencephalography. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Magnetoencephalography. Positron-Emission Tomography. Sensitivity and Specificity. Videotape Recording

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Epilepsy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16636252.001).

[ISSN] 1526-632X

[Journal-full-title] Neurology

[ISO-abbreviation] Neurology

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / K23 NS051637; United States / NINDS NIH HHS / NS / P01 NS002808; United States / NINDS NIH HHS / NS / R01 NS020806; United States / NINDS NIH HHS / NS / R01 NS038992; United States / NINDS NIH HHS / NS / R01 NS046516

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms?

Tuberous sclerosis complex and von Hippel-Lindau disease are distinct autosomal dominant tumor suppressor syndromes that can exhibit similar renal phenotypes and seem to share some signaling pathway components.

Similarities exist in the current clinical management of, and the newly identified potential therapeutic approaches for, these conditions.

This Review summarizes the pathophysiologic and therapeutic overlap between tuberous sclerosis complex and von Hippel-Lindau disease and highlights the results of recent drug trials in these settings.

[MeSH-major] Kidney Diseases, Cystic / genetics. Kidney Neoplasms / genetics. Tuberous Sclerosis / genetics. von Hippel-Lindau Disease / genetics

[MeSH-minor] Adenoma, Oxyphilic / genetics. Angiomyolipoma / genetics. Carcinoma, Renal Cell / genetics. Cell Proliferation. Humans. Hypoxia-Inducible Factor 1 / metabolism. Signal Transduction. Tumor Suppressor Proteins / metabolism

Genetic Alliance. consumer health - Tuberous sclerosis.

MedlinePlus Health Information. consumer health - Kidney Cancer.

MedlinePlus Health Information. consumer health - Kidney Cysts.

MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19240728.001).

[ISSN] 1745-8331

[Journal-full-title] Nature clinical practice. Nephrology

[ISO-abbreviation] Nat Clin Pract Nephrol

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA122346; United States / NIDDK NIH HHS / DK / DK061458; United States / PHS HHS / / DODPR064135; United States / PHS HHS / / DODTS050008

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1; 0 / Tumor Suppressor Proteins

[Number-of-references] 148